NOVI, Mich.--(BUSINESS WIRE)--Delphinus Medical Technologies, a pioneering medical imaging company that developed the SoftVue™ Breast Tomographic Ultrasound, announced today that Rama Gundlapalli has joined the company as Vice President of Engineering. Mr. Gundlapalli brings more than 30 years of experience in product development and engineering, having worked in startup, small and fortune 500 companies and applying knowledge in research and development to build out successful commercial product pipelines.
“Rama’s vast experience in commercial development and helping to build numerous successful product pipelines will serve Delphinus well as we advance our SoftVue technology,” said Scott White, president and CEO, Delphinus Medical Technologies, Inc. “We continue to grow our team with industry leaders and I’m excited to have Rama’s experience in delivering successful products to market. Rama’s background in clinical imaging specific to hardware and software platforms will certainly expedite the adoption of the SoftVue into the breast healthcare market.”
Gundlapalli comes to Delphinus after most recently holding the position of senior director of research collaborations at Siemens Healthineers. He supervised the Advanced Therapies US/Canada collaboration Team with a focus on driving leadership transformation and executing innovation and product development strategies across interventional neurology, pulmonology, cardiology, liver cancer and skeletal diseases. Prior to Siemens, Mr. Gundlapalli worked at Northgate Technologies Inc. helping develop and commercialize laparoscopic insufflators and lithotripsy systems; CareFusion (acquired by BD) and DePuy Synthes (J&J MedTech) leading the development and launch of their high-flex total knee systems. In addition, Mr. Gundlapalli has nurtured his entrepreneurial side with three startups of his own.
“I’m excited to be part of Delphinus Medical Technologies and support our mission. The team is dedicated and passionate about making SoftVue the market leading solution for early detection of breast cancer in women with dense breasts,” said Rama Gundlapalli. “Like many, my family has a history of breast cancer, and it is my goal to support bringing SoftVue to healthcare providers across the country in order to help save lives.”
SoftVue is approved by the U.S. Food and Drug Administration (FDA) as an adjunct to mammography for screening women with dense breasts. At least 40% of US women have dense breasts, and compounding the increased risk, dense breast tissue like cancer, typically appears white on a mammogram, making it more challenging to detect cancer early. When paired with mammography, SoftVue has been shown to identify up to 20 percent more cancers, while also reducing false positives and decreasing unnecessary call-backs and biopsies in women with dense breasts.
Delphinus continues to leverage the breakthrough performance of SoftVue to expand commercialization and is adding to its commercial infrastructure to support national implementation of robust dense breast screening programs to benefit patients in targeted accounts.
About Delphinus Medical Technologies, Inc.
Headquartered in Novi, Michigan, Delphinus Medical Technologies, Inc., is a pioneering medical imaging company that developed SoftVue™, featuring the first circular array transducer technology. The patented technology is a 3D whole-breast ultrasound tomography system that delivers no radiation, requires no compression, and images the entire breast with a single scan. To learn more, visit our website and follow us on LinkedIn.
